ARS Prescription drugs to Showcase Innovation and Current Information on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Bronchial asthma and Immunology (AAAAI) Annual Scientific Assembly
- Oral presentation on an efficacy examine carried out in Japanese sufferers evaluating anaphylaxis signs throughout oral meals problem with neffy because the preliminary remedy in comparison with website historic knowledge on intramuscular auto-injectors, antihistamines and inhalers; sufferers receiving neffy had decrease symptom scores inside 10 minutes, supporting neffy as a needle-free choice for administration of anaphylaxis
- neffy was proven to be within the protected and efficacious vary for youngsters 4 years or older who weigh greater than 15 kilograms
- Findings in Chinese language research confirms U.S. knowledge and bracketed pharmacokinetic (PK) and pharmacodynamic (PD) profiles, reveal neffy’s comparable efficacy and security below numerous circumstances together with self-administration, allergic rhinitis, infectious rhinitis, in allergy challenges and with repeat dosing, in contrast with intermuscular injection
SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) — ARS Prescription drugs, Inc. (Nasdaq: SPRY), a biopharmaceutical firm devoted to empowering at-risk sufferers and their caregivers to raised shield sufferers from extreme allergic reactions that might result in anaphylaxis, introduced right now that 9 displays will likely be featured on the 2025 American Academy of Allergy, Bronchial asthma and Immunology (AAAAI) Annual Scientific Assembly, February 28 to March 3, in San Diego, California. The oral presentation and posters will function knowledge from a variety of research, together with pharmacokinetics and pharmacodynamics of intranasal epinephrine below regular and numerous circumstances, physiological responses between adults and youngsters who’re administered epinephrine, and the pre-treatment journey of sufferers with allergic circumstances. Along with the displays, ARS Pharma will take part in and host a wide range of onsite actions throughout the assembly.
“We look ahead to sharing further findings from our complete scientific analysis program with the broader allergy group at AAAAI and count on that the info will proceed to construct on the prevailing sturdy knowledge on the efficacy and security of intranasal epinephrine administration,” stated Sarina Tanimoto, MD, PhD, Co-Founder and Chief Medical Officer of ARS Pharma the maker of neffy (epinephrine nasal spray), the primary and solely FDA-approved needle-free remedy for Sort I allergic reactions, together with anaphylaxis, in adults and youngsters who weigh ≥30 kg (66 lbs.). “As one of many main firms actively conducting analysis on this crucial area, we stay dedicated to advancing the scientific data base of epinephrine so we are able to contribute to the allergy group.”
The entire checklist of displays and assembly actions is beneath. Abstracts may be considered at annualmeeting.aaaai.org. Attendees are inspired to go to the ARS Pharma sales space (#1315), oral and poster displays in addition to the product theatre to be taught extra about neffy.
| Oral Presentation – March 1, 2025 | |
| Time: | 2:45 p.m. – 2:55 p.m. PST |
| Title: | Superior Efficacy of Epinephrine Nasal Spray for the Reduction of Signs Following an Oral Meals Problem |
| Speaker: | Kyohei Takahashi, MD, MPH, PhD |
| Room: | Conference Heart, Higher Stage, Room 6B |
| Poster ID: | 571 |
| Poster Shows – March 1, 2025 | |
| Poster Presentation #1 | |
| Time: | 9:45 a.m. – 10:45 a.m. PST |
| Title: | Pharmacokinetics and Pharmacodynamics of Single Dose of Epinephrine Nasal Spray and Guide Intramuscular Injections by way of HCP and Self-administration in Chinese language Topics Underneath Regular Circumstances |
| Authors: | Yun Liu, MD, Shumin Wang, PhD, Miao Yu, MD, PhD, Pingya Hu, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD |
| Poster ID: | 297 |
| Poster Presentation #2 | |
| Time: | 9:45 a.m. – 10:45 a.m. PST |
| Title: | Persistence to Therapy in Sufferers with Allergic Circumstances Requiring Epinephrine Auto-Injector Prescription (EAI Rx) |
| Authors: | Autumn Burnette, MD, Raffi Tachdjian, MD, Nicole M. Chase, MD, Sarina Tanimoto, MD, PhD, Ayman Kafal, PhD, MPH |
| Poster ID: | 302 |
| Poster Presentation #3 | |
| Time: | 9:45 a.m. – 10:45 a.m. PST |
| Title: | Pharmacokinetics of Epinephrine Nasal Spray below Varied Circumstances |
| Authors: | David M. Fleischer, MD, John Oppenheimer, MD, David Bernstein, MD, Thomas B. Casale, MD, Jonathan M. Spergel, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD |
| Poster ID: | 290 |
| Poster Presentation #4 | |
| Time: | 9:45 a.m. – 10:45 a.m. PST |
| Title: | Distinction in Physiology Between Adults and Kids in Response to Epinephrine Administration |
| Authors: | Matthew J. Greenhawt, MD, David M. Fleischer, MD, Thomas B. Casale, MD, Michael A. Kaliner, MD, Neetu Talreja, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD |
| Poster ID: | 289 |
| Poster Presentation #5 | |
| Time: | 9:45 a.m. – 10:45 a.m. PST |
| Title: | Understanding the Pre-Therapy Journey of Sufferers with Allergic Circumstances: Insights from Affected person Demographics and Diagnostic Pathways |
| Authors: | Raffi Tachdjian, MD, Autumn Burnette, MD, Nicole M. Chase, MD, Sarina Tanimoto, MD, PhD, Ayman Kafal, PhD, MPH |
| Poster ID: | 291 |
| Poster Presentation #6 | |
| Time: | 9:45 a.m. – 10:45 a.m. PST |
| Title: | Pharmacokinetics and Pharmacodynamics of Single Dose of Epinephrine Nasal Spray and Guide Intramuscular Injection in Chinese language Topics Underneath Allergic Rhinitis Circumstances |
| Authors: | Jianting Wang, MD, PhD, Shumin Wang, PhD, Miao Yu, MD, PhD, Jiaowei Lu, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD |
| Poster ID: | 318 |
| Poster Presentation #7 | |
| Time: | 9:45 a.m. – 10:45 a.m. PST |
| Title: | Whole Nasal Symptom Scores Stay Constant in Response to Repeated Nasal Allergen Challenges |
| Authors: | Anne Ok. Ellis, MD, Michael A. Kaliner, MD, Carlos A. Camargo, Jr., MD, DrPH, John Oppenheimer, MD, David Bernstein, MD, Thomas B. Casale, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD |
| Poster ID: | 483 |
| Poster Presentation #8 | |
| Time: | 9:45 a.m. – 10:45 a.m. PST |
| Title: | Pharmacokinetics and Pharmacodynamics of Repeat Dose of Epinephrine Nasal Spray and Guide Intramuscular Injection in Chinese language Topics Underneath Regular Circumstances |
| Authors: | Shumin Wang, PhD, Jianting Wang, MD, PhD, Miao Yu, MD, PhD, Jiaowei Lu, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD |
| Poster ID: | 317 |
| Onsite Actions | |
| Joint Congress Opening Ceremony and Welcome Reception | |
| Date: | February 27, 2025 |
| Time: | 4:15 p.m. – 5:45 p.m. PST |
| Location: | Conference Heart – Floor Stage Room 6A |
| Non-CME Company Discussion board (Product Theatre) | |
| Date: | February 27, 2025 |
| Time: | 6:30 p.m. – 8:30 p.m. PST |
| Location: | Marriott Marquis San Diego Marina – North Tower, Foyer Stage Grand Ballroom Salon 4 |
| Exhibit Sales space | |
| Date: | February 28-March 2, 2025 |
| Location: | #1315 |
About neffy®
neffy is an intranasal epinephrine product for sufferers with Sort I allergic reactions because of insect stings or bites, meals, medicinal merchandise, different allergens, in addition to idiopathic or train induced anaphylaxis that might result in life-threatening anaphylaxis.
INDICATION AND IMPORTANT SAFETY INFORMATION FOR neffy (epinephrine nasal spray)
INDICATION
neffy 2 mg is indicated for emergency remedy of Sort I allergic reactions, together with anaphylaxis, in grownup and pediatric sufferers who weigh 30 kg or larger.
IMPORTANT SAFETY INFORMATION
It’s endorsed that sufferers are prescribed and have quick entry to 2 neffy nasal sprays always. Within the absence of scientific enchancment or if signs worsen after preliminary remedy, administer a second dose of neffy in the identical nostril with a brand new nasal spray beginning 5 minutes after the primary dose.
neffy is to be used within the nostril solely.
Advise sufferers when to hunt emergency medical help for shut monitoring of the anaphylactic episode and within the occasion additional remedy is required.
Absorption of neffy could also be affected by underlying structural or anatomical nasal circumstances.
Administer with warning to sufferers who’ve coronary heart illness; epinephrine might irritate angina pectoris or produce ventricular arrhythmias. Arrhythmias, together with deadly ventricular fibrillation, have been reported, notably in sufferers with underlying cardiac illness or taking cardiac glycosides, diuretics, or anti-arrhythmics.
The presence of a sulfite in neffy shouldn’t deter use.
neffy might alter nasal mucosa for as much as 2 weeks after administration and improve systemic absorption of nasal merchandise, together with neffy.
Sufferers with sure medical circumstances or who take sure medicines for allergic reactions, despair, thyroid problems, diabetes, and hypertension, could also be at larger threat for antagonistic reactions.
Epinephrine can briefly exacerbate the underlying situation or improve signs in sufferers with the next: hyperthyroidism, Parkinson’s illness, diabetes, renal impairment. Epinephrine ought to be administered with warning in sufferers with these circumstances, together with aged sufferers and pregnant girls.
Opposed reactions to neffy might embrace throat irritation, intranasal paresthesia, headache, nasal discomfort, feeling jittery, paresthesia, fatigue, tremor, rhinorrhea, nasal pruritus, sneezing, belly ache, gingival ache, hypoesthesia oral, nasal congestion, dizziness, nausea, and vomiting.
These aren’t all the doable unintended effects of neffy. To report suspected antagonistic reactions, contact ARS Prescription drugs Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For extra data on neffy, please see Full Prescribing Data at www.neffy.com.
About Sort I Allergic Reactions Together with Anaphylaxis
Sort I allergic reactions are critical and probably life-threatening occasions that may happen inside minutes of publicity to an allergen and require quick remedy with epinephrine, the one FDA-approved remedy for these reactions. Whereas epinephrine auto-injectors have been proven to be extremely efficient, there are nicely revealed limitations that end in many sufferers and caregivers delaying or not administering remedy in an emergency state of affairs. These limitations embrace worry of the needle, lack of portability, needle-related security issues, lack of reliability, and complexity of the gadgets. There are roughly 40 million folks in the US who expertise Sort I allergic reactions. Of this group roughly 20 million folks have been identified and handled for extreme Sort I allergic reactions which will result in anaphylaxis, however (in 2023, for instance) solely 3.2 million crammed their lively epinephrine auto-injector prescription, and of these, solely half constantly carry their prescribed auto-injector. Even when sufferers or caregivers carry an auto-injector, greater than half both delay or don’t administer the gadget when wanted in an emergency.
About ARS Prescription drugs, Inc.
ARS Prescription drugs is a biopharmaceutical firm devoted to empowering at-risk sufferers and their caregivers to raised shield sufferers from allergic reactions that might result in anaphylaxis. The corporate is commercializing neffy® 2 mg (commerce title EURneffy® within the EU) (beforehand known as ARS-1), an epinephrine nasal spray indicated within the U.S. for emergency remedy of Sort I allergic reactions, together with anaphylaxis, in grownup and pediatric sufferers who weigh 30 kg or larger, and within the EU for emergency remedy of allergic reactions (anaphylaxis) because of insect stings or bites, meals, medicinal merchandise, different allergens, in addition to idiopathic or train induced anaphylaxis in adults and youngsters who weigh 30 kg or larger. For extra data, go to www.ars-pharma.com.
ARS Pharma Investor Contact:
Justin Chakma
ARS Pharma
justinc@ars-pharma.com
ARS Pharma Media Contact:
Christy Curran
Sam Brown Inc.
615.414.8668
christycurran@sambrown.com
Word of Disclosure: ARS Pharma is an advertiser with SnackSafely.com.
